

**S1 Table.** First-line chemotherapy regimens and outcomes in patients with B-cell lymphoma receiving second-line or more treatments

Variable	RTX (n=22)	TCE (n=12)	p-value
First-line chemotherapy			
R-CHOP	13 (59.1)	6 (50.0)	0.610
R-MVP	6 (27.3)	0	0.069
R-CVP	1 (4.5)	3 (25.0)	0.115
Rituximab plus bendamustine	2 (9.1)	2 (16.7)	0.602
R-GemOX	0	1 (8.3)	0.353
Re-admission due to COVID-19	3 (13.6)	4 (33.3)	0.211
Extended isolation due to low Ct value <sup>a)</sup>	15 (68.2)	10 (83.3)	0.439
In-hospital mortality	6 (27.3)	6 (50.0)	0.265
COVID-19-related mortality	3 (13.6)	6 (50.0)	0.040

Values are presented as number (%). COVID-19, coronavirus disease 2019; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine, and prednisone; R-GemOX, rituximab plus gemcitabine, and oxaliplatin; R-MVP, rituximab plus methotrexate, vincristine, and procarbazine; RTX, rituximab; TCE, T-cell engager. <sup>a)</sup>Ct value < 25.